Paris. March 24, 2021. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Sven Zimmermann as Chief Executive Officer, effective April 19th, 2021. Sven brings an extensive leadership experience in biotech companies’ financial and corporate strategy.
March 16-17. 2021 (fully digital format). Inotrem is thrilled to participate to HYBRID 2021, the first Health Bioscience Research Industry Days that represents the complete ecosystem in life science in France, organized by ARIIS, AVIESAN, Leem, BPI France and France Biotech. During two days, researchers, biotech companies and representatives of
Paris, Limoges, Nancy (France). February 3rd, 2021 – Today, the CoviTREM-1 consortium, regrouping Nancy and Limoges teaching hospitals with Inotrem, a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, announces that it has completed the patients’ inclusion of its Phase IIa clinical study with a total of 60 patients
Paris, December 24. 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that its Phase IIa study of nangibotide, the company’s lead product, for the treatment of severe forms of COVID-19 has been declared “National Priority Research” by the French government’
Paris, December 21. 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announces today that an independent Data Monitoring Committee (DMC) recommends continuation of the Phase IIa study of nangibotide for the treatment of severe forms of COVID-19 hospitalized in intensive care units
October 7, 2020 – Today, the CoviTREM-1 consortium, regrouping Nancy and Limoges teaching hospitals with Inotrem, announces that it has enrolled its first patients. CoviTREM-1 is funded as part of the call for proposals PSPC-COVID, managed on behalf of the Government by Bpifrance as part of the “Investissements d’Avenir” Program
Paris, September 25 . 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced today the appointment of Delphine Joyeux as Director of Regulatory Affairs and Quality Assurance and Simon Lambden as Head of Medical Science.
Inotrem’s clinical study on Covid-19 was selected by the French government to be part of its €78 M action plan aimed at reinforcing the countries’ research capabilities for therapeutic solutions.
Intensive Care Medicine publishes the results of Inotrem’s study which demonstrated the safety and tolerability of its lead compound, nangibotide, in patients suffering from septic shock.
Paris, February 11th, 2020. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes, announced a €5M capital increase financed by Fountain Healthcare Partners, a leading Irish venture capital firm with offices in Dublin and New
January 20. 2020. Paris, France. Inotrem was chosen to join the French Tech 120. This program, launched by the President of the Republic and the Prime Minister in September 2019, is dedicated to support the development of fast growing startups. The French Tech Mission brings together some 50 French Tech
January 21. 2020. Paris, France. Inotrem has entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein (sTREM-1). This agreement consolidates existing ties between Roche Diagnostics and Inotrem who are jointly developing since 2017 an in vitro assay
March 24. 2020. Brussels, Belgium. Inotrem will attend the 40th International Symposium on Intensive Care & Emergency Medicine which stands as one of the largest meeting in its field, attracting more than 6200 participants. During the Symposium, Inotrem will present a poster showing for the first time the association between
February 27-28, 2020. Washington DC. Inotrem will attend the 3CT Workshop (Critical Care Clinical Trialists) that will take place at the French Embassy on February 27th and 28th 2020 in Washington DC. During the 2-days Symposium, Inotrem will present the design of its ASTONISH Phase IIb clinical trial for Nangibotide
January 13-16, 2020. San Francisco. Inotrem will participate to the annual J.P. Morgan Healthcare Conference. It is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
December 3, 2019. Nancy. Cecile Jouclas, Inotrem’s Administrative and Financial Officer, will participate to the Deeptech Tour organized by the BPI. Cecile will be a host at the workshop “What tools to finance your deeptech project?” that will take place on the Université de Lorraine’s campus. Throughout France, the Deeptech
Paris (France). November 21. 2019. Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today it has initiated its Phase IIb ASTONISH trial to evaluate nangibotide in the treatment of septic shock and has enrolled the first patient
October 8-12 in Chania, Crete, Greece. Marc Derive, Co-founder and CSO of Inotrem, will present new preclinical data during the 18th ESS congress and 9th Congress of the IFSS, entitled “TREM-1 pharmacological inhibition by LR12/nangibotide improves survival and controls vascular leakage during experimental endotoxic shock in mice” in a session
28 September – 2 October 2019 in Berlin, Germany. European Society of Intensive Care Medicine’s (ESICM) annual congress attracts audiences of over 6,000 physicians, anesthetists, trainees and nursing and allied health professionals, every year, from every continent and 97 different countries. A diverse faculty of more than 300 international speakers
Paris, September 12th. 2019. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes,announced today a €39 million Series B financing led by Morningside Ventures, joined byInvus with participation from existing investors Andera Partners, Sofinnova Partners
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2018 – Legal notices
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices